Mayoly is reaching an important milestone in its commitment to the energy transition and the fight against climate change. We are proud to announce that our near-term decarbonization trajectory, aimed at limiting global warming to 1.5°C by 2030, has been validated by the Science Based Targets initiative (SBTi).
This validation confirms our desire to combine economic growth and environmental responsibility and reflects on the need for decisive action to limit the global temperature increase and call on all our stakeholders to take similar steps.
By significantly reducing our greenhouse gas (GHG) emissions, we are actively participating in the global effort to combat global warming.
An ambitious trajectory by 2030, Mayoly is committed to:
- Reduce our GHG emissions from scopes 1 and 2 by 50% (direct and indirect emissions linked to the energy used)
- Reduce our emissions linked to the supply chain (scope 3) by 55% per million euros of added value
The climate emergency pushes us to act now. Every action counts for a greener future. These priorities transform the way we operate, from resource management to the way we produce, distribute our products and manage our vehicle fleet.
Review of our actions in 2024
- A strengthened eco-responsible approach: 100% renewable electricity and a responsible purchasing charter
As part of our commitment, we have taken several immediate and concrete measures. Since January 2024, all our industrial sites have been powered by 100% renewable electricity (ENR), an important step in optimizing our energy consumption and reducing our carbon footprint as a preamble to our energy sobriety plan and decarbonization roadmap developed this year.At the same time, we have implemented a responsible purchasing policy in 2024. More than 50% of our suppliers have already signed this charter, allowing us to guarantee that our supply chain meets the highest environmental and social standards. This approach reinforces our commitment to a more sustainable future at every stage of our operations.
- Why is a carbon footprint essential for a company?
A carbon footprint is a key tool for understanding a company’s impact on the climate. It measures the GHG emissions generated by the company, whether direct or indirect. To achieve effective decarbonization objectives, it is essential to know precisely where these emissions come from. This assessment helps us to set clear objectives, such as those validated by the SBTi, and to adjust our actions accordingly.
- Why it is urgent to act?
Climate change is a global and urgent challenge. Each company must take its share of responsibility to limit its impact. By reducing its GHG emissions and pollution across its entire value chain, a companynot only contributes to the fight against global warming and the preservation of the environment and the health of all living things, but it also meets the growing expectations of stakeholders – customers, investors, and regulators. For MAYOLY, acting now as a responsible player means being ready to seize the opportunities of a market that is increasingly focused on sustainability.
- An inspiring model for the sector
With this validation, MAYOLY joins a global movement of decarbonization in the pharmaceutical industry. Our trajectory validated by the SBTi is a model of strong commitment, illustrating our desire to play a leading role in the ecological transition of our sector. At MAYOLY, we are convinced that every action counts. Our commitment to decarbonization will contribute to building a more environmentally sustainable future.
- Our 2023 carbon footprint
Under the SBTi initiative, total reported emissions are 80,008 tonnes of CO2 for 2019 and 82,014 tonnes of CO2 for 2023 respectively.
Scopes 1 and 2 emissions: down -18% in 2023 compared with 2019 (7985 TCO2eq. in 2023 vs. 9761 TCO2eq. in 2019), in line with our trajectory.
Scope 3 emissions per million euros of added value: -5% in 2023 vs. 2019.
As for our ambition to reduce our scope 3 emissions associated with the purchase of goods and services, the transport and distribution of our products, business and personal travel, waste and the end-of-life of products, we are at the very beginning of the journey.
Announcement – Executive Vice President & Chief Financial Officer
Sophie DESLOGES has an extensive experience in all areas of the finance role. She has held key roles at Forvia, Wabtec/Faiveley, GE Power Conversion and Deloitte.
Sophie holds a degree from the Paris Superior Business School (ESCP) and is a certified public accountant. She is currently deepening her knowledge with an Executive Master’s in “Change and Sustainability” at HEC Paris.
Her track record and numerous successes in her previous companies in all aspects of financial performance will be major assets in supporting the Group’s development and accelerating MAYOLY’s performance
SAVE THE DATE : Mayoly Gastro Days 2024
Mayoly Gastro Days 2024: Your connection to the latest advancements and insights in hepato-gastroenterology!
Connect on December 13-14 as we team up with 11 leading European experts to discuss pivotal advances in hepato-gastroenterology.
Expect engaging discussions, valuable expert insights, and shared practices to elevate your expertise in gastroenterology.
Be informed of the full program and REGISTER for this special event here
Sustainability Report 2023
Our CSR approach is supported by our purpose, “improving health and well-being for everyone to offer a better daily life for each individual,” and contributes to our ambition of becoming a global leader in public health.
We are thrilled to welcome Adam Zarnowski as our new General Manager for Poland and Central Eastern Europe (CEE).
With over 30 years of experience in the healthcare industry, Adam brings a wealth of expertise and leadership. He has successfully led commercial activities across the CEE region, driving significant growth and innovation.
His extensive experience in both commercial and academic settings, combined with a PhD from the Medical University of Warsaw, equips him to expand MAYOLY in this key region.
At Mayoly, we are dedicated to supporting patients. We are pleased to introduce the Logbook, a guide designed to help patients prepare effectively before a colonoscopy.
The importance of a good preparation
We launched this project in order to raise awareness among patients about the importance of preparation, and then about the bowel cleansing solution, before a colonoscopy. This document provides clear information, practical advice and tips to ensure that the examination goes as good as possible.
A guide by a patient for patients
This guide was developed in partnership with Pierre-Louis Attwell, a navigator and patient with Crohn’s disease. Having undergone multiple medical procedures, Pierre-Louis can authentically speak about the importance of the preparation before a colonoscopy. His personal experience perfectly illustrates why proper preparation is crucial for a successful procedure. It is important to remember that this exam is critical for detecting precancerous lesions. The quality of the examination largely depends on the preparation, including the bowel preparation.
Find Pierre-Louis’s interview here.
What you will find within the logbook
This document is designed to serve as a guide throughout the preparation process before a colonoscopy. Inside, you will find:
· A clear explanation of what bowel cleansing solution is and why it is so important,
· Practical recommendations for drinking bowel cleansing effectively,
· Advice on the low-residue diet recommended before the colonoscopy,
· Definitions of key terms related to the procedure and preparation,
· A checklist at the end of the guide to follow the essential steps.
Download it!
To view and download the Logbook, click here. This guide is available for free, and we encourage you to share it with anyone who might benefit from it.
Our Executive Committee is welcoming a new member: Gael Chalvon Demersay as Mergers & Acquisitions, Business Development and Alliances Director, effective on June 17, 2024.He succeeds Emmanuel Botzung who has left the group.
He graduated from HEC (Hautes Etudes Commerciales) Paris (Paris Business School) with a Master’s degree in Corporate Finance and Strategy and began his career in 2014 as a consultant at the Boston Consulting Group.
In 2019, he was appointed Director of Strategy and M&A at Laboratoires Juvisé Pharmaceuticals, where he was responsible for external growth alliances and business development.
Together, let’s continue to grow in a changing world and build our future! Discover our successes and 2023 highligts.
We aspire to become a benchmark in consumer healthcare and to become one of the world’s Top 20 Consumer Healthcare companies in our markets, by moving towards greater well-being and closeness to our stakeholders. This ambition is based on what unites us – our values, our strong French industrial base, our world-famous brands and the talent of our teams – but also on what makes us complementary – our business areas, our product portfolios and our international presence. This new ambition for the Group is accompanied by a new visual territory with a strong conviction, a new name to gather the various entities, with a new logo and a new signature.
Seven new subsidiaries opened
L’ouverture de 7 nouvelles filiales marque une étape essentielle dans la finalisation de l’intégration d’IPSEN CHC au sein de MAYOLY et permet au Groupe de poursuivre son déploiement à l’international dans des pays à fort potentiel. Ces récentes ouvertures portent à 23 le nombre de ses filiales à travers le monde.
La filiale en Tunisie, ouverte en juillet 2023, prend en charge la promotion d’un portefeuille unifié de solutions de santé, en gastroentérologie, à travers le pays.
Les filiales basées en Algérie, République Tchèque, Lituanie, Pologne, Roumanie et Slovaquie, ouvertes en janvier 2024, marquent une étape importante dans la poursuite de l’internationalisation de Mayoly. Ces nouvelles filiales ont également pour mission de promouvoir et commercialiser le portefeuille unifié de solutions de santé en gastroentérologie, en s’appuyant sur un solide réseau de distribution local.
Cette expansion représente une étape importante dans l’ambition de MAYOLY d’étendre sa présence mondiale et continuer à investir sur de nouveaux marchés.
Fort de son réseau mondial avec 23 filiales à travers le monde et plus de 2 200 collaborateurs, MAYOLY est à présent positionné, pour continuer son développement afin d’apporter des bénéfices concrets aux patients et aux consommateurs avec des solutions de santé et de bien-être efficaces, fiables et accessibles au plus grand nombre, à travers le monde.